Publications by authors named "Li Jerry"

Chronic pain is a pervasive, disabling, and understudied feature of multiple sclerosis (MS), a progressive demyelinating and neurodegenerative disease. Current focus on motor components of MS disability combined with difficulties assessing pain symptoms present a challenge for the evaluation and management of pain in MS, highlighting the need for novel methods of assessment of neural signatures of chronic pain in MS. We investigate chronic pain in MS using MS-related trigeminal neuralgia (MS-TN) as a model condition focusing on gray matter structures as predictors of chronic pain.

View Article and Find Full Text PDF
Article Synopsis
  • Alterations in the ALK gene are crucial for the development of anaplastic large cell lymphoma (ALCL), and crizotinib is an approved treatment for pediatric patients with this type of cancer.
  • The study included data from pediatric patients treated with crizotinib, focusing on how the drug is processed in the body and its safety and effectiveness at different doses.
  • Results showed that crizotinib dosing appropriately adjusted for patient size led to similar drug exposure across different ages and tumor types, with a notable relationship between higher doses and better treatment responses, except for severe cases of neutropenia.
View Article and Find Full Text PDF

Cullin-RING ligases (CRLs) ubiquitylate specific substrates selected from other cellular proteins. Substrate discrimination and ubiquitin transferase activity were thought to be strictly separated. Substrates are recognized by substrate receptors, such as Fbox or BCbox proteins.

View Article and Find Full Text PDF

E3 ubiquitin ligases, in collaboration with E2 ubiquitin-conjugating enzymes, modify proteins with poly-ubiquitin chains. Cullin-RING ligase (CRL) E3s use Cdc34/UBE2R-family E2s to build Lys48-linked poly-ubiquitin chains to control an enormous swath of eukaryotic biology. Yet the molecular mechanisms underlying this exceptional linkage specificity and millisecond kinetics of poly-ubiquitylation remain unclear.

View Article and Find Full Text PDF

Ubiquitylation is catalyzed by coordinated actions of E3 and E2 enzymes. Molecular principles governing many important E3-E2 partnerships remain unknown, including those for RING-family GID/CTLH E3 ubiquitin ligases and their dedicated E2, Ubc8/UBE2H (yeast/human nomenclature). GID/CTLH-Ubc8/UBE2H-mediated ubiquitylation regulates biological processes ranging from yeast metabolic signaling to human development.

View Article and Find Full Text PDF

Protein ubiquitylation typically involves isopeptide bond formation between the C-terminus of ubiquitin to the side-chain amino group on Lys residues. However, several ubiquitin ligases (E3s) have recently been identified that ubiquitylate proteins on non-Lys residues. For instance, HOIL-1 belongs to the RING-in-between RING (RBR) class of E3s and has an established role in Ser ubiquitylation.

View Article and Find Full Text PDF

The recent proliferation of NISQ devices has made it imperative to understand their power. In this work, we define and study the complexity class NISQ, which encapsulates problems that can be efficiently solved by a classical computer with access to noisy quantum circuits. We establish super-polynomial separations in the complexity among classical computation, NISQ, and fault-tolerant quantum computation to solve some problems based on modifications of Simon's problems.

View Article and Find Full Text PDF

Background: The diversity in the genomic landscape of advanced and metastatic tumors calls for combination therapies based on the genomic signature associated with each tumor. Determining safe and tolerable doses for novel combinations of oncology drugs is essential for a precision medicine approach, but can also require dose reductions. Trametinib, palbociclib, and everolimus are among the targeted therapies most often used in novel combinations at our precision medicine clinic.

View Article and Find Full Text PDF
Article Synopsis
  • E3 ligases play a critical role in regulating proteins that have terminal destabilizing motifs (degrons), but how they distinguish true substrates from similar proteins remains unclear.
  • The study focuses on KLHDC2, which targets specific Gly-Gly degrons and exhibits a unique dual assembly model that influences its substrate binding and E3 ligase activation.
  • KLHDC2's ability to form a self-inactivated tetramer and its interaction with true substrates helps ensure that only appropriate proteins are marked for degradation, effectively acting as a molecular timer that prevents E3 inactivation until the right targets are identified.
View Article and Find Full Text PDF

Quantum technology promises to revolutionize how we learn about the physical world. An experiment that processes quantum data with a quantum computer could have substantial advantages over conventional experiments in which quantum states are measured and outcomes are processed with a classical computer. We proved that quantum machines could learn from exponentially fewer experiments than the number required by conventional experiments.

View Article and Find Full Text PDF

Purpose: Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC). Lenvatinib, a multikinase inhibitor, and pembrolizumab, a PD-1 inhibitor, have shown efficacy and tolerability in patients with HCC, and adding this combination to TACE may enhance clinical benefit.

Protocol: LEAP-012 is a prospective, double-blind randomized phase 3 study.

View Article and Find Full Text PDF

Introduction: Chronic cough is a highly problematic symptom for patients with idiopathic pulmonary fibrosis (IPF); limited therapeutic options are available. We evaluated gefapixant, a P2X3 receptor antagonist, for the treatment of chronic cough in IPF.

Methods: This randomized, double-blind, placebo-controlled, crossover study included subjects with IPF.

View Article and Find Full Text PDF

Introduction: Dacomitinib and gefitinib are irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) indicated for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) and EGFR-activating mutations. Pharmacokinetic (PK) studies in healthy volunteers suggested that acid-reducing drugs such as proton pump inhibitors (PPI) decreased dacomitinib and gefitinib exposure by limiting the pH-dependent absorption. This analysis retrospectively evaluates the effect of concomitant PPI use on dacomitinib exposure and on progression-free survival (PFS) and overall survival (OS) in patients treated with dacomitinib 45 mg QD or gefitinib 250 mg QD in a 1:1 randomized phase 3 study (ARCHER 1050).

View Article and Find Full Text PDF

Background And Objective: Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the second-line treatment of patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. Lorlatinib is metabolized by cytochrome P450 (CYP) 3A and contraindicated with strong CYP3A inducers because of significant transaminase elevation. This phase I, open-label, two-period study evaluated the impact of a moderate CYP3A inducer, modafinil, on the safety and pharmacokinetics of lorlatinib.

View Article and Find Full Text PDF

Common approaches to studying mechanisms of chronic pain and sensory changes in pre-clinical animal models involve measurement of acute, reflexive withdrawal responses evoked by noxious stimuli. These methods typically do not capture more subtle changes in sensory processing nor report on the consequent behavioral changes. In addition, data collection and analysis protocols are often labour-intensive and require direct investigator interactions, potentially introducing bias.

View Article and Find Full Text PDF
Article Synopsis
  • A phase I open-label trial evaluated the pharmacokinetics and safety of glasdegib in participants with moderate to severe hepatic impairment compared to healthy controls.
  • 24 participants were divided into groups, receiving a single oral dose of 100 mg of glasdegib, and the study looked at plasma concentration measures over time.
  • Results indicated that moderate hepatic impairment did not significantly affect glasdegib levels, while severe impairment led to lower plasma exposure, but no adverse events were reported, suggesting no need for dose adjustments based on liver function.*
View Article and Find Full Text PDF

The development of new analgesic drugs has been hampered by the inability to translate preclinical findings to humans. This failure is due in part to the weak connection between commonly used pain outcome measures in rodents and the clinical symptoms of chronic pain. Most rodent studies rely on the use of experimenter-evoked measures of pain and assess behavior under ethologically unnatural conditions, which limits the translational potential of preclinical research.

View Article and Find Full Text PDF

VRC01 is a first-in-class, potent, broadly neutralizing antibody that targets the CD4 binding site of gp120 on HIV-1 viruses, and is under development as a novel HIV therapeutic. This study utilized population pharmacokinetic (PK) modeling to characterize VRC01 PK to guide dosing selection for ongoing phase II clinical trials in pediatric patients. Combining VRC01 PK data from 3 adult and 1 infant clinical trials, a total of 1,475 VRC01 serum concentrations from 100 participants were used in the analysis (40 infants and 60 adults).

View Article and Find Full Text PDF
Article Synopsis
  • * Patients may develop gastroesophageal reflux disease (GERD) requiring proton pump inhibitors (PPIs) like rabeprazole, which can affect the stomach's acid secretion and have lasting effects even after 24 hours.
  • * Research aimed to analyze the absorption of dacomitinib and found that the use of rabeprazole notably influenced its pharmacokinetics, with a transit compartment model best describing how dacomitinib is absorbed in the body.
View Article and Find Full Text PDF

Correction for 'Understanding of binding energy calibration in XPS of lanthanum oxide by in situ treatment' by Jerry Pui Ho Li et al., Phys. Chem.

View Article and Find Full Text PDF

Rare earth oxides have seen increased usage over the years in batteries and catalysts. Due to their unique electronic properties, they are the subject of fundamental and practical interest. However, the complexity in their electronic structures makes unambiguous characterization, such as X-ray photoelectron spectroscopy (XPS), very challenging.

View Article and Find Full Text PDF

Zika virus is an emerging flavivirus that causes the neurodevelopmental congenital Zika syndrome and that has been linked to the neuroinflammatory Guillain-Barré syndrome. The absence of a vaccine or a clinically approved drug to treat the disease combined with the likelihood that another outbreak will occur in the future defines an unmet medical need. Several promising drug candidate molecules have been reported via repurposing studies, high-throughput compound library screening, and de novo design in the short span of a few years.

View Article and Find Full Text PDF

Background: The activity of MP1, a pyrrolomycin, was studied in MYCN amplified neuroblastoma (NB) alone and combined with temsirolimus (TEM).

Methods: Activity of MP1 was tested in MYCN amplified (BE-2c, IMR) and non amplified (SKN-AS) NB cells. The effect of MP1 on MYCN, MCL-1, cleaved PARP, LC3II/LC3I, bcl-2, BAX, and BRD-4 were determined by western blot and RNAseq.

View Article and Find Full Text PDF
Article Synopsis
  • Despite Hong Kong's wealth and high health outcomes, 8.4% of surveyed participants reported not seeking medical care due to financial constraints.
  • Those unable to access healthcare were predominantly income-poor and exhibited higher levels of anxiety, stress, and poorer overall health quality compared to the general population.
  • The study highlights significant healthcare inequities, indicating that individuals with greater health needs often face barriers in receiving necessary medical care.
View Article and Find Full Text PDF